Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for treating patients with atrial fibrillation as part of the AZALEA-TIMI 71 Study. The trial ...

Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, ...

A new study highlights that the experimental blood-thinner abelacimab significantly reduces bleeding risks in atrial fibrillation patients compared to standard treatments like rivaroxaban. In trial ...

Researchers have found that Factor XI inhibitors, such as abelacimab, reduce bleeding risks in atrial fibrillation patients more effectively than standard anticoagulants.

That's significant because the GI tract is the most common site of bleeding with DOACs, and this type of bleeding is the only one for which DOACs do not have a better risk profile ...

Patients with atrial fibrillation are typically prescribed an anticoagulant, or blood thinner, to reduce the risk of stroke, but many may discontinue ...

The results will support the company’s application for expanded labeling of its popular Farapulse pulsed field ablation ...

Amiodarone effectively maintains sinus rhythm in patients with atrial fibrillation, and although dronedarone is less effective it has a better safety profile. The choice of antiarrhythmic drug (or ...

A Fitbit got a reporter to see his doctor — and ultimately go under the knife. Are wearables the next wave in heart health?